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Abstract: It is not known if anti-tumor necrosis factor (anti-TNF) agents provoke only apoptosis of lamina 
propria mononuclear cells (LPMC) engaged in inflammatory processes or whether it’s a general phenomenon 
concerning all LPMC. In this study we carried out an immunohistochemical analysis of the expression of several 
apoptosis-related proteins (active caspase-3, Bax, Bcl-2, Fas, TNFR1, CD4, and CD8) in uninflamed mucosa 
in Crohn’s disease (CD) patients treated with anti-TNF agents. 16 CD patients (mean age 34 ± 11, mean dis-
ease duration 7 ± 5 years) were included in the study. 10 patients were treated with infliximab and 6 — with 
adalimumab. The expression of active caspase 3, Bax, Bcl-2, Fas, TNFR1 and CD8 in LPMC did not change 
significantly after the therapy. We concluded that anti-TNF antibodies did not promote LPMC apoptosis in 
uninflamed tissues. This is in contrast to the phenomena observed in inflamed tissues. These data show that 
anti-TNF antibodies rather restore the susceptibility to apoptosis of LPMC in inflamed areas of the gut in CD, 
than directly induce LPMC apoptosis; otherwise the anti-TNF antibodies should have also induced apoptosis 
in the uninflamed mucosa. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 3, 239–243)
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Introduction
The mechanisms of action of anti-TNF antibodies 
(infliximab, IFX, and adalimumab, ADA) used in the 
treatment of Crohn’s disease (CD) are still not well 
known. It is believed that one of the crucial pheno-
mena leading to the down-regulation of inflammatory 
infiltration in the intestinal tissue is the induction of 
apoptosis of immune cells [1-3]. Study from our gro-
up showed that the proportion of apoptotic lamina 
propria mononuclear cells (LPMC) is increased after 
anti-TNF therapy, as evidenced in mucosal biopsies 
taken from inflamed areas of the colon in patients 
with CD [4]. However, the question remains whether 
anti-TNF antibodies also induce programmed cell 
death of LPMC in uninflamed areas of the gut.
In the current study we carried out an immunohi-
stochemical analysis of the effect of IFX and ADA on 
the expression of apoptosis-related proteins in LPMC 
in intestinal biopsies taken from uninflamed areas of 
the colon mucosa in patients with CD. 
Material and methods
The inclusion criterion for the study was an exacer-
bation of the disease in spite of the administration of 
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maximal doses of standard therapy for CD (3–4 g daily 
of aminosalicylates for at least 12 weeks, steroids in 
stable doses for at least 4 weeks and/or azathioprine 
2–2.5 mg/kg body weight for at least 12 weeks) [5]. 
16 patients participated in the study (9 females and 
7 males, mean age 34 ± 11 years). Mean CD duration 
was 7 ± 5 years. 
The study was approved by the Bioethics Com-
mittee of the Poznan University of Medical Sciences. 
After a written consent was obtained, each patient 
underwent a colonoscopy before starting anti-TNF 
therapy. Multiple biopsies were taken from the unin-
flamed (macroscopically normal) areas of the colon. 
Disease clinical activity was assessed by calculating the 
Crohn’s Disease Activity Index (CDAI). The patients 
then received either three doses of IFX 5 mg/kg body 
weight intravenously in weeks 0, 2 and 6, or ADA 
160 mg subcutaneously in week 0, 80 mg in week 2, and 
40 mg every other week until week 12, in accordance 
with the current recommendations with regard to 
biological therapy [5]. 10 patients were treated with 
IFX and 6 with ADA. After the induction of anti-TNF 
therapy was finished, the patients were admitted to 
our Department to carry out follow-up investigations. 
These also included colonoscopy with tissue sampling 
from the same uninflamed areas of the colon. 
Tissue samples obtained during colonoscopy were 
fixed in 10% neutral buffered formalin and then 
embedded in paraffin. H+E staining was performed 
and immunohistochemical expression (the ABC 
technique, in accordance with Hsu et al.) of selected 
proteins was assessed in LPMC as previously descri-
bed [4,6]. The following primary antibodies were 
used: anti-active caspase 3 (R&D Systems, Minne-
apolis, USA, No AF835, concentration 1µg/mL), 
anti Bcl-2 (DAKO, Glostrup, Denmark, No M088701, 
dilution 1:500), anti-Bax (DAKO, No A353301, dilu-
tion 1:2000), anti-Fas (Leica Monocastra, Newcastle, 
UK, No NCL-FAS-310, dilution 1:200), anti-TNFR1 
(Abcam, San Diego, USA, No Ab 19139, dilution 
1:2000), anti-CD4 (DAKO, No M731001, dilution 
1:200) and anti-CD8 (DAKO, No M710301, dilution 
1:300). Semiquantitative 12-point Remmele and 
Stegner Immunoreactive Score (IRS) was used to 
assess the expression of active caspase 3, Bcl-2 and 
Bax. IRS takes into account the percentage of positive 
cells (0% — 0 pts; < 10% — 1 pt; 11–50% — 2 pts; 
51–80% — 3 pts; > 80% — 4 pts) and the intensity 
of staining (graded 0–3 pts) [7]. To obtain the final 
score of protein expression the aforementioned 
components of IRS were multiplied. In case of CD4, 
CD8, Fas, and TNFR1 a modified HercepTest was 
applied. This score takes into account the intensity 
and completeness of membrane staining, as well as 
the number of positive cells, and is graded 0–3 pts [8]. 
The appropriate statistical analysis was performed. 
The differences in proteins expression were evaluated 
using the Wilcoxon non-parametric test. Statistical 
significance was assumed at p < 0.05. 
Results and discussion
The biological therapy resulted in a statistically signi-
ficant decrease of CDAI (266 vs. 98 pts; p < 0.05). 
H+E staining did not reveal any histological signs 
of active inflammation in the lamina propria of the 
endoscopically-uninflamed intestinal tissue samples. 
We found the immunohistochemical expression of 
investigated proteins mainly in LPMC and entero-
cytes, single polymorphonuclear cells were also im-
munoreactive (Figure 1). The expression of an active 
caspase 3, Bax, Bcl-2 (as a well as a pro-apoptotic Bax/
/Bcl-2 ratio), Fas, TNFR1 and CD8 in LPMC did not 
change significantly after the anti-TNF therapy. Only 
the number of CD4 LPMC decreased significantly 
(Figure 2). The expression of the investigated proteins 
in the epithelial cells was also quantified. However, 
anti-TNF treatment did not change the expression of 
any of the assessed proteins in the enterocytes. 
In our study we tried to answer the question 
whether anti-TNF agents provoke only the apoptosis 
of the LPMC engaged in inflammatory processes 
or whether it is a general phenomenon affecting all 
LPMC, also in uninflamed mucosa. This question 
is essential because it was shown that both ADA 
and IFX can induce apoptosis of peripheral blood 
monocytes, which are not directly involved in the in-
flammatory processes in the intestines in IBD [9,10]. 
On the other hand, Ten Hove et al. showed that only 
CD3/CD28-stimulated Jurkat T cells undergo apop-
tosis after the administration of IFX, as opposed to 
unstimulated Jurkat T cells [11].
The main finding of this study is the demonstra-
tion that LPMC from uninflamed areas of the gut 
did not die in programmed cell death mechanism 
after anti-TNF antibody treatment. This confirms 
that IFX and ADA regulate disturbed apoptosis of 
inflammatory cells sensitizing LPMC to pro-apoptotic 
stimuli rather than provoke a programmed cell death 
by itself. The susceptibility to apoptosis of LPMC is 
locally down-regulated probably due to the influence 
of several proinflammatory cytokines. For example 
IL-6, which is present at the site of inflammation 
in high concentration, in complex with its soluble 
receptor, can bind to membrane gp130 protein in 
lymphocytes [12,13]. This results in signal transducer 
and activator of transcription 3 (STAT3) activation. 
STAT3 induces the expression of genes encoding the 
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Figure 2. The influence of anti-TNF antibodies on the expression of (A): an active caspase 3 Bcl-2, Bax; (B): Fas, TNFR1, 
CD4 and CD8 in lamina propria mononuclear cells of uninflamed mucosa of CD patients. IRS — immunoreactive score. 
*p < 0.05
Figure 1. Immunohistochemical localization of active caspase 3, CD4, CD8, Bax, Bcl-2, Fas and TNFR1 in colonic 
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anti-apoptotic proteins belonging to Bcl-2 family pro-
teins like Bcl-2 or BclX. Another cytokine which can 
be involved in this phenomenon is IL-12 [13]. IL-12 
after binding to its receptor can activate the STAT4 
pathway, thereby inhibiting the activation of initiator 
caspases. This interrupts the activation of caspase 
cascade leading to disturbances in apoptotic cellular 
elimination. IFX and ADA, being strong anti-inflam-
matory drugs, down-regulate the local concentration 
of IL-6 and IL-12, which, in turn, sensitizes LPMC to 
pro-apoptotic stimuli. This leads to the stimulation 
of inflammatory cells’ programmed cell death and 
reduces the inflammatory infiltration in the gut. These 
phenomena do not affect the uninflamed tissue in CD, 
because here, the apoptosis of LPMC is probably not 
initially disturbed. 
Another possible explanation of the difference 
in effect of IFX or ADA on LPMC apoptosis in 
inflamed and uninflamed tissues is the difference in 
cellular milieu. Atreya et al. showed that anti-TNF 
antibodies are able to induce T-cell apoptosis only 
when they are co-cultured with transmembrane TN-
F-expressing (tmTNF) CD14 macrophages [2]. The 
authors speculated that macrophages in inflamed 
mucosa stimulate lymphocytes’ resistance to apoptosis 
by binding of their tmTNF to TNFR2 on T cells. IFX 
and ADA bind to tmTNF on macrophages and in that 
way may interfere with the tmTNF/TNFR2 pathway. 
Thus, anti-TNF antibodies indirectly provoke the 
programmed cell death of T cells. 
In other studies it was shown that there is a de-
crease in the number of immune suppressor cells in 
inflamed mucosa in CD and/or their functions are 
altered. Moreover, anti-TNF therapy restores mu-
cosal homeostasis and supports immunosuppressive 
reactions, which are disturbed under inflammatory 
conditions. A study by Ricciardelli et al. revealed 
that the number of mucosal CD4 CD25 (FOXP3+) 
T regulatory cells was significantly reduced in active 
CD, when compared with healthy conditions. This was 
reversed after IFX administration, but not after the 
conventional CD therapy [14]. Vos et al. showed also 
that anti-TNF antibodies induce regulatory CD206 
macrophages in an Fc-dependent signal pathway [15]. 
This leads to the inhibition of activated and immune-
stimulated proliferation of T cells. In summary, it can 
be hypothesized that the restoration of the suppressive 
functions of different cell types (which function is al-
tered in inflamed mucosa) after anti-TNF antibodies 
administration, can indirectly enhance the apoptotic 
elimination of mucosal T cells. 
Another observation in our study is the signi-
ficant decrease in the number of CD4 LPMC in 
healthy tissues. CD4 cells are believed to be the 
most important inflammatory cells engaged in CD 
pathogenesis. Anti-TNF antibodies can probably 
induce the apoptosis of peripheral blood CD4 cells 
and down-regulate the CD4 migration from the blo-
od vessel into the tissues [9]. One can speculate that 
those two aforementioned phenomena can explain 
the significant decrease in CD4 LPMC also in the 
uninflamed intestinal tissue after the administration 
of anti-TNF agents.
Conclusions
We have for the first time, to the best of our know-
ledge, directly demonstrated in intestinal specimens, 
that anti-TNF antibodies do not promote LPMC 
apoptosis in the uninflamed colon mucosa in CD. 
This suggests that the induction of LPMC apoptosis 
in inflamed areas of the intestines observed after the 
administration of anti-TNF agents may represent 
a secondary phenomenon to the down-regulation of 
proinflammatory and anti-apoptotic cytokine concen-
tration, or secondary to the restoration of the altered 
cellular milieu. 
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